Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients
Cancer · 2023-06 · 129 (11) · 1723-1734
DOI: 10.1002/cncr.34716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 04.03.2023. Verfasst von Zeynep Eroglu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Melanoma. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have substantially improved overall survival in patients with advanced melanoma; however, the lack of biomarkers to monitor treatment response and relapse remains an important clinical challenge. Thus, a reliable biomarker is needed that can risk‐stratify patients for disease recurrence and predict response to treatment.
Methods
A retrospective analysis using a personalized, tumor‐informed circulating tumor DNA (ctDNA) assay on prospectively collected plasma samples ( n = 555) from 69 patients with advanced melanoma was performed. Patients were divided into three cohorts: cohort A ( N = 30), stage III patients receiving adjuvant ICI/observation; cohort B ( N = 29), unresectable stage III/IV patients receiving ICI therapy; and cohort C ( N = 10), stage III/IV patients on surveillance after planned completion of ICI therapy for metastatic disease.
Results
In cohort A, compared to molecular residual disease (MRD)‐negative patients, MRD‐positivity was associated with significantly shorter distant metastasis‐free survival (DMFS; hazard ratio [HR], 10.77; p = .01). Increasing ctDNA levels from the post‐surgical or pre‐treatment time point to after 6 weeks of ICI were predictive of shorter DMFS in cohort A (HR, 34.54; p < .0001) and shorter progression‐free survival (PFS) in cohort B (HR, 22; p = .006). In cohort C, all ctDNA‐negative patients remained progression‐free for a median follow‐up of 14.67 months, whereas ctDNA‐positive patients experienced disease progression.
Conclusion
Personalized and tumor‐informed longitudinal ctDNA monitoring is a valuable prognostic and predictive tool that may be used throughout the clinical course of patients with advanced melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
- Natera, Inc, Austin, Texas, USA.
ORCID-Profile: Zeynep Eroglu, Charuta C Palsuledesai
Zitieren
APA
Eroglu, Z., Krinshpun, S., Kalashnikova, E., Sudhaman, S., Ozturk Topcu, T., Nichols, M., Martin, J., Bui, K. M., Palsuledesai, C. C., Malhotra, M., Olshan, P., Markowitz, J., Khushalani, N. I., Tarhini, A. A., Messina, J. L., & Aleshin, A. (2023). Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer, 129(11), 1723-1734. https://doi.org/10.1002/cncr.34716
Vancouver
Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, et al. Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023;129(11):1723-1734. doi:10.1002/cncr.34716
BibTeX
@article{Eroglu2023,
author = {Eroglu, Zeynep and Krinshpun, Shifra and Kalashnikova, Ekaterina and Sudhaman, Sumedha and Ozturk Topcu, Turkan and Nichols, Matt and Martin, Justin and Bui, Katherine M and Palsuledesai, Charuta C and Malhotra, Meenakshi and Olshan, Perry and Markowitz, Joseph and Khushalani, Nikhil I and Tarhini, Ahmad A and Messina, Jane L and Aleshin, Alexey},
title = {Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients},
journal = {Cancer},
year = {2023},
volume = {129},
number = {11},
pages = {1723--1734},
doi = {10.1002/cncr.34716}
}
EUVIMED